



## **Quidel to Present at BIOCOM San Diego Investor Conference on November 15**

November 8, 2006

SAN DIEGO--(BUSINESS WIRE)--Nov. 8, 2006--Quidel Corporation (NASDAQ:QDEL), a leading provider of point-of-care (POC) rapid diagnostic tests, today announced that it will present at the BIOCOM San Diego Investor Conference to be held November 14-16, 2006 at the San Diego Marriott Del Mar Hotel.

Caren L. Mason, Quidel's President and Chief Executive Officer, is scheduled to speak on Wednesday, November 15, 2006, at 11:00 a.m. Pacific time (2:00 p.m. Eastern time) and will discuss its strategic initiatives, business developments and market opportunities.

Investors may access a live audio Internet webcast via the Investor Information section of the Company's Web site at [www.quidel.com](http://www.quidel.com). A replay of the presentation and Q&A will be available for 14 days following the conference at the above Web address.

### About Quidel

Quidel Corporation serves to enhance the health and well being of people around the globe through the discovery, development, manufacturing and marketing of rapid diagnostic solutions at the point of care (POC) in infectious diseases and reproductive health. Marketed under the leading brand name of QuickVue(R), the portfolio currently includes tests that aid in the diagnosis of several disease or condition states, including influenza, respiratory syncytial virus, Fecal Occult Blood, Strep A, pregnancy, bacterial vaginosis, infectious mononucleosis, H. pylori and Chlamydia. Quidel's products are sold to healthcare professionals with a focus on the physician office lab and acute care markets through leading medical distribution partners on a worldwide basis. Quidel's Specialty Products Group (SPG) develops research products in the fields of oncology and bone health with future point-of-care applications. By building value in rapid diagnostic tests, Quidel provides leadership to the industry and among healthcare professionals allowing for the movement of patient testing out of the central laboratory setting and into the physician office, urgent care and other outpatient settings where rapid testing and treatment has an impact on clinical outcomes and provides an economic benefit. For more information, visit [www.quidel.com](http://www.quidel.com), [www.flutest.com](http://www.flutest.com), or [www.colorectal-test.com](http://www.colorectal-test.com).

### CONTACT: Quidel Corporation

Paul E. Landers, Chief Financial Officer  
858-552-7962

or

Lippert/Heilshorn & Associates  
Don Markley/Bruce Voss, 310-691-7100

SOURCE: Quidel Corporation